13 completed, 10 terminated, 3 withdrawn, 2 recruiting. 16 Phase 2, 8 Phase 4, 7 Phase 1, 5 Phase 3, 1 Early Phase 1.
Follow RATG: new trials by email Literature Review of RATG trials Research Report on RATG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML Rabbit Anti thymocyte globulin, Busulfan, Fludarabine - AML, Childhood, Aml | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 68 | 2024-11-15 | 2026-08-24 |
| 1 vs 7 RATG Infusions in Renal Transplantation RATG, Basiliximab - Kidney Replacement | Active not recruiting | Mario Negri Institute for Pharmacological Research | 75 | 2024-07-30 | 2025-09-04 | |
| Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) Treosulfan, Fludarabine Phosphate, Tacrolimus - Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2022-04-19 | 2026-03-09 |
| Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation - Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2021-01-14 | 2024-10-26 | |
| Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies Bortezomib, Busulfan, Cyclophosphamide - Beta Thalassemia Major, Sickle Beta 0 Thalassemia | Early Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2020-12-29 | 2024-10-24 | |
| Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide - Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 2 | Terminated | M.D. Anderson Cancer Center | 1 | 2020-08-19 | 2025-06-29 |
| rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT) Privigen, Thymoglobulin, Plasma Exchange - Kidney Transplantation | Phase 3 | Completed | Institute for Clinical and Experimental Medicine | 17 | 2020-07-27 | 2024-08-15 |
| Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide - Non-Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 40 | 2020-06-16 | 2026-06-17 |
| Autologous Transplant To End NMO Spectrum Disorder Rituximab, Cyclophosphamide, Mesna - Neuromyelitis Optica, Devic's Disease | Phase 2 / Phase 3 | Withdrawn | Northwestern University | 2019-11-01 | 2019-11-20 | |
| Veloxis de Novo Kidney Transplant ECSWD Tacrolimus Extended Release Oral Tablet [Envarsus], Mycophenolate Mofetil, Mycophenolic Acid Oral Product - Kidney Transplantation, Immunosuppression | Phase 4 | Unknown | Simon Tremblay, PharmD, PhD | 60 | 2019-06-21 | 2020-05-13 |
| Cardiac Safe Transplants for Systemic Sclerosis Rituximab, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Scleroderma | Phase 2 / Phase 3 | Terminated | Northwestern University | 9 | 2018-05-17 | 2020-08-12 |
| Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Romidepsin, Busulfan, Fludarabine - Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 23 | 2017-12-08 | 2025-09-19 |
| Maximizing Outcome of Multiple Sclerosis Transplantation Cyclophosphamide, Mesna, rATG - Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Terminated | Northwestern University | 66 | 2017-11-08 | 2021-01-11 |
| Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients Basiliximab, Thymoglobulin - Kidney Transplant Rejection, Kidney Transplant; Complications | Phase 4 | Completed | Coordinación de Investigación en Salud, Mexico | 100 | 2016-12-01 | 2019-11-15 |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) Busulfan, Fludarabine, Clofarabine - Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 11 | 2015-09-14 | 2024-02-22 |
| Stem Cell Transplantation for Stiff Person Syndrome (SPS) Autologous Hematopoietic Stem Cells, Cyclophosphamide, Mesna - Stiff-Person Syndrome | Phase 1 / Phase 2 | Terminated | Northwestern University | 23 | 2014-10-01 | 2021-01-27 |
| A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia rabbit ATG, Cyclosporine, Levamisole - Aplastic Anemia | Phase 2 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2014-08-01 | 2026-02-11 |
| Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients Belatacept, Tacrolimus, Mycophenolate - Implant or Graft; Rejection | Phase 4 | Completed | Columbia University | 57 | 2014-06-01 | 2021-02-10 |
| Single Dose rATG for Renal Allograft Rejection rATG - Acute (Cellular) Renal Allograft Rejection | Phase 4 | Unknown | The Methodist Hospital Research Institute | 30 | 2014-03-01 | 2020-09-03 |
| Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies CliniMACS® CD34 Reagent System, Fludarabine, Melphalan - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 2 | Terminated | Weill Medical College of Cornell University | 2 | 2012-10-26 | 2018-07-11 |
Showing 20 of 31. Sign in to see all of them.
Leukemia (5) · Leukemia, Myeloid, Acute (5) · Lymphoma (4) · Myelodysplastic Syndromes (4) · Lymphoma, Non-Hodgkin (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Kidney Failure, Chronic (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Neuromyelitis Optica (2) · Rejection, Psychology (2) · Scleroderma, Systemic (2) · Anemia, Aplastic (1) · Anemia, Diamond-Blackfan (1) · Anemia, Hypochromic (1) · Anemia, Sickle Cell (1)
M.D. Anderson Cancer Center (6) · Northwestern University (6) · Fred Hutchinson Cancer Center (2) · University of Cincinnati (2) · Columbia University (1) · Coordinación de Investigación en Salud, Mexico (1) · Everett Meyer (1) · Institute for Clinical and Experimental Medicine (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Mario Negri Institute for Pharmacological Research (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Ohio State University Comprehensive Cancer Center (1) · Simon Tremblay, PharmD, PhD (1) · The Methodist Hospital Research Institute (1) · University of Nebraska (1)
United States (25) · China (1) · Czechia (1) · Italy (1) · Mexico (1)
Richard Burt, MD (6) · E. Steve Woodle, MD (2) · Adele Rike, PharmD (1) · Amin Alousi, MD (1) · Everett H Meyer, MD, PhD (1) · Giuseppe Remuzzi, MD (1) · Gustavo Martinez-Mier, MD (1) · Jeremy S Connors, MD (1) · Jonathan Brammer, MD (1) · Koen van Besien, MD, PhD (1) · Kris M Mahadeo (1) · Kris M Mahadeo, MD (1) · Lauri Burroughs, MD (1) · Margaret MacMillan, MD (1) · Mark A. Hardy, MD (1)
PMID 1090310, PMID 12622583, PMID 16699456, PMID 17093248, PMID 18497677, PMID 19714613, PMID 21401720, PMID 22850297, PMID 24622416, PMID 25083614, PMID 26465152, PMID 26696251, PMID 27053235, PMID 27208317, PMID 28198767, PMID 32612255, PMID 33318163, PMID 40458542
P01HL122173 (1), U10HL069294 (1)